Cofetuzumab (anti-CCK4)

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab182763-100μg	100μg	现货
Ab182763-1mg	1mg	现货
Ab182763-5mg	5mg	现货
Ab182763-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: PTK7

Accession#: Q13308 (2) CCK4 (2) Gene ID: 5754 (2) PTK7 (2) Receptor Tyrosine Kinase (2808)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Cofetuzumab (anti-CCK4)
别名	考非妥珠单抗 \| 考菲妥珠单抗(抗 CCK4)
英文别名	8430404F20Rik antibody \| CCK 4 antibody \| CCK-4 antibody \| Colon carcinoma kinase 4 antibody \| Human colon carcinoma kinase 4 (CCK4) mRNA complete cds antibody \| Inactive tyrosine-protein kinase 7 antibody \| mPTK7/CCK4 antibody \| OTTHUMP00000217016 antibo
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	PTK7
种属反应性	人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	27.1 kDa (Light Chain) & 50.9 kDa (Heavy Chain), under reducing conditions; 197.2 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95% (SDS-PAGE&SEC)
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1869928-62-0
分子类型	抗体

关联靶点（人）

PTK7 Tbio 无活性的酪氨酸蛋白激酶 7(Inactive tyrosine-protein kinase 7) (0 活性数据)

点击查看靶蛋白信息： PTK7

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

图片

Flow Cytometry: Cofetuzumab (anti-CCK4) (Ab182763)

Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Flow Cytometry: Cofetuzumab (anti-CCK4) (Ab182763)

Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of A431 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Flow Cytometry: Cofetuzumab (anti-CCK4) (Ab182763)

Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Flow Cytometry: Cofetuzumab (anti-CCK4) (Ab182763)

Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of A549 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.